Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

RCT (n=1222) reports sotagliflozin resulted in significantly lower composite of total number of deaths from cardiovascular causes and hospitalisations for heart failure vs. placebo (51.0 vs. 76.3; hazard ratio, 0.67; 95% CI, 0.52 to 0.85; P<0.001).

New England Journal of Medicine